Streetbeat News

Regulatory

TRNR

VGK

Interactive Strength has successfully passed EU compliance for its CLMBR product and will begin fulfilling orders in Europe and the UK immediately.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:08 am

ACXP

Acurx Pharmaceuticals has reported promising research results for its antibiotic ibezapolstat, developed in collaboration with Leiden University Medical Center. The findings highlight ibezapolstat's unique properties, such as lacking cross-resistance with other antibiotics and not promoting vancomycin-resistant Enterococcus. Acurx is preparing to advance ibezapolstat into international Phase 3 clinical trials for treating C. difficile Infection (CDI).

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:07 am

UTHR

United Therapeutics is set to present five presentations and one poster at the CHEST 2024 Annual Meeting, focusing on its commercial and development portfolio. Key data from the BREEZE open-label extension study of Tyvaso DPI will highlight long-term outcomes and dosing for pulmonary arterial hypertension patients.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:05 am

FAAS

Trading has been halted for an unspecified asset at 6:55:00 a.m. ET due to pending news. The halt indicates that significant information is expected to be released, which could impact the asset's price once trading resumes.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:55 am

IMMP

Immutep has received a €2.19 million R&D tax incentive payment from the French government under the CIR scheme. This financial boost supports their ongoing research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:11 am

CPRX

Catalyst Pharmaceuticals' FIRDAPSE has been approved in Japan for treating Lambert-Eaton Myasthenic Syndrome (LEMS), marking a significant milestone for the company and its sub-licensee, DyDo Pharma. This approval expands FIRDAPSE's reach beyond the U.S., where it is already a leading therapy for LEMS.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:08 am

LLY

Eli Lilly announced that Japan has approved its drug Kisunla (Donanemab-azbt) for early symptomatic Alzheimer's disease. The approval was based on data from the TRAILBLAZER-ALZ 2 Phase 3 clinical study.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:07 am

NVO

Novo Nordisk's CEO announced that their drug Ozempic will be eligible for U.S. price negotiations within a year, aligning with expectations for 2027. The Senate will scrutinize the high prices of Ozempic and Wegovy, amid concerns over counterfeit versions.

Portfolio Pulse from Benzinga Neuro

September 24, 2024 | 9:48 am

FXI

SPY

The Governor of China's Central Bank announced that the Medium Term Lending Rate and Lending Prime Rate will be reduced further. This move is likely aimed at stimulating economic growth by making borrowing cheaper.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 9:26 am

FXI

SPY

China's Central Bank Governor announced a reduction in mortgage rates for existing homes to support the steady recovery of prices in the economy. This move is part of broader efforts to shore up the real estate market.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 9:25 am